Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2 studies found for:    lymphoma OR CLL | lirilumab
Show Display Options
Rank Status Study
1 Recruiting Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Lymphocytic Leukemia
Interventions: Drug: Lirilumab;   Drug: Rituximab
2 Recruiting An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab;   Biological: Daratumumab;   Drug: Pomalidomide;   Drug: Dexamethasone

Study has passed its completion date and status has not been verified in more than two years.